AUS
NZ
UK
CA
USA
IND
On July 27, 2026, Shane Bohnen, Senior Vice President and General Counsel of Bio-Techne Corp (NASDAQ:TECH), filed a disclosure detailing significant changes in his beneficial ownership following stock transactions executed on July 23, 2026. The report highlights multiple acquisitions and sales of shares, alongside a broad portfolio of derivative securities including stock options and restricted stock units. These disclosures offer valuable insight into insider equity positions and executive compensation structures within the biotechnology firm.
Key Points
- Bio-Techne Corp traded on NASDAQ under ticker TECH
- Shane Bohnen, SVP and General Counsel, completed stock transactions on July 23, 2026, with filing submitted July 27, 2026
- Bohnen purchased 448 shares at $47.60 each and sold 344 shares at $71.77 each in non-derivative trades
- Post-transactions, Bohnen holds 7,697 shares of common stock directly, plus extensive derivative holdings including stock options and restricted stock units with varied vesting schedules
Details of Executive Stock Transactions and Ownership Adjustments
According to the Form 4 filing, Shane Bohnen executed two separate non-derivative transactions on July 23, 2026. Initially, he acquired 448 shares of Bio-Techne common stock at $47.60 per share, designated with transaction code "M," typically indicating a purchase or exercise. Later that day, Bohnen sold 344 shares at $71.77 per share, coded "F," representing a disposition. These sequential transactions resulted in a net increase in his direct beneficial ownership.
Following these trades, Bohnen's direct ownership totaled 7,697 shares of Bio-Techne common stock held outright in his name, with no indirect holdings via trusts or entities. This significant direct stake underscores his personal financial commitment to the company’s performance and governance.
Comprehensive Derivative Securities Portfolio and Vesting Timelines
Beyond common stock, Bohnen's holdings include a substantial array of derivative securities reflecting Bio-Techne’s executive compensation framework. The filing reveals stock options with exercise prices ranging from $47.60 up to $120.46 per share, alongside restricted stock units (RSUs) and performance-based equity awards. These instruments are subject to diverse vesting schedules and performance conditions, representing potential future economic interests contingent on meeting specified criteria.
Vesting periods for these derivatives span from August 7, 2026, through August 15, 2035. Notably, options priced at $47.60 are fully vested as of August 7, 2026. Other grants, such as options at $94.52, vest in four equal installments between August 15, 2024, and August 15, 2026. Performance-based RSUs and options require achievement of performance goals and certification by the administrator on or after target dates.
Varied Stock Option Grants Across Multiple Years and Strike Prices
Bohnen’s option portfolio includes grants from several vintage years, each with distinct exercise prices and expiration dates. These include 448 shares at $47.60, 8,944 shares at $66.97 (expiring August 5, 2027), 3,460 shares at $120.46, and 3,508 shares at $94.52. Additional grants at $73.76, $84.61, $74.91, and $53.60 cover share amounts ranging from 3,338 to 17,897, reflecting staggered compensation awards over time.
This range of exercise prices indicates grants issued during different fiscal periods, likely tied to annual equity compensation or promotions. Lower strike prices such as $47.60 and $53.60 may currently be in-the-money, whereas higher-priced options require stock appreciation to gain intrinsic value. Such diversification is common for long-tenured executives and aligns incentives with shareholder value creation over extended horizons.
Restricted Stock Unit Awards Featuring Tiered Vesting
Bohnen’s compensation includes multiple RSU grants, which entitle him to receive shares upon vesting without exercise costs. The filing details several tranches: 49 RSUs vesting August 15, 2026; 3,338 RSUs vesting in two equal parts on August 15, 2026, and August 15, 2027; and 6,996 RSUs vesting in three equal portions on August 15 of 2026, 2027, and 2028.
This tiered vesting schedule promotes retention by providing incremental equity value over multiple years. Unlike options, RSUs deliver direct equity upon vesting based on the stock price at that time, forming a key component of Bohnen’s long-term incentive package typical in biotechnology executive compensation.
Performance-Linked Equity Awards
Bohnen’s portfolio also includes performance-contingent awards comprising 4,802 performance RSUs vesting by August 15, 2026, 10,012 RSUs vesting on or after August 15, 2027, and 13,992 RSUs vesting on or after August 15, 2028, all contingent on meeting performance targets. Additionally, he holds performance stock options covering 12,924 shares subject to similar vesting conditions and expiration on or after August 15, 2026.
These awards vest fully or partially upon achievement of specified goals, with certification by the compensation administrator. This structure aligns executive rewards with company-specific or individual performance metrics, differentiating these holdings from time-based grants.
Transaction Timing and Filing Compliance
The stock transactions occurred on Wednesday, July 23, 2026, with the Form 4 filing submitted on Sunday, July 27, 2026. This four-business-day interval complies with SEC Rule 16(a)-3, which mandates filings within two business days post-transaction. Transaction codes "M" and "F" correspond to acquisitions and dispositions, respectively.
The filing was signed by Andrew Nick, attorney-in-fact for Bohnen under a prior power of attorney, a common practice for busy executives. The transactions appear routine, consistent with compensation-related equity management rather than discretionary trading.
Beneficial Ownership and Reporting Obligations Under Section 16
As a Senior Vice President and General Counsel, Bohnen is a Section 16 reporting person under the Securities Exchange Act of 1934, requiring timely disclosure of ownership changes. He is neither a director nor a 10% owner but must file Form 4 due to his officer status. His direct ownership of 7,697 shares combined with extensive derivative holdings represents significant personal financial exposure to Bio-Techne’s equity.
All disclosed securities are held directly by Bohnen, with no indirect interests reported. Investors often monitor such insider transactions as potential indicators of confidence in company prospects, though they may also reflect compensation realizations or diversification strategies.
Aggregate Economic Exposure from Derivative Holdings
Summing Bohnen’s derivative securities reveals exposure to approximately 76,261 underlying shares via stock options, 30,693 shares through restricted stock units, and 41,530 shares tied to performance-based awards. Including his 7,697 directly held shares, his total potential beneficial ownership could exceed 155,000 share-equivalents depending on vesting and exercise outcomes.
This extensive derivative portfolio is typical for senior executives in publicly traded life sciences firms, where long-term equity incentives form a major compensation component. The staggered vesting and varied strike prices create a dynamic portfolio aligned with shareholder value creation.
Form 4 Filing Accuracy and Legal Certification
The Form 4 contains standard legal certifications warning that intentional misstatements or omissions constitute federal crimes under 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). It also references OMB Number 3235-0287 and estimates an average 0.5-hour burden per filing, though complex disclosures may require more time.
All information is sourced directly from the SEC EDGAR database and reflects only transactions and holdings disclosed by or on behalf of Shane Bohnen as of July 27, 2026. The filing does not provide details on Bohnen’s personal trading strategies or motivations. Form 4 disclosures are publicly accessible via the SEC EDGAR system and contribute to transparency around insider ownership at NASDAQ-listed companies.
